Patients diagnosed with chronic lymphocytic leukemia who have a specific gene mutation typically don’t survive longer than three years, but a drug approved Monday, based on science out of Dana-Farber, could change that. Matthew Davids (Dana-Farber) is quoted.
Trending News
Search for Babesiosis Treatment Gets a New Map
New clues to help fight tick-borne disease
Can an AI ‘Co-Scientist’ Accelerate Cancer Research?
Nearly $7 million funds agentic AI tools to assist investigations into cancer’s most pressing…
First Large-Scale Study Shows How Doctors Use AI in Medicine
Which practitioners use artificial intelligence in the clinic, and what do they ask?